Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
SAN DIEGO, March 09, 2017 -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's fourth quarter and full year 2016 financial results will be released on Monday, March 13, 2017 at 4:01 p.m. Eastern Time. Company management will host a conference call on Monday, March 13, 2017, at 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
To participate by telephone, please dial (855) 780-7196 (Domestic) or (631) 485-4867 (International). The conference ID number is 85861485. The live audio webcast can be accessed via the Investor Relations’ section of the Company's website at www.apricusbio.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived webcast will remain available for 30 days following the live call.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product candidates currently in development. Vitaros is a product candidate in the United States for the treatment of erectile dysfunction, which is in-licensed from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc (Allergan). RayVa is our product candidate in Phase 2 development for the treatment of the circulatory disorder Raynaud’s phenomenon, secondary to scleroderma, for which we own worldwide rights.
For further information on Apricus, visit http://www.apricusbio.com.
Vitaros™ is Apricus’ trademark in the United States, which is pending registration and subject to the agreement with Allergan. Vitaros® is a registered trademark of NexMed International Limited, and will be assigned to Ferring B.V. worldwide, excluding the United States. RayVa™ is Apricus’ trademark, which is registered in certain countries throughout the world and pending registration in the United States.
CONTACT: Institutional / Retail Investors: Matthew Beck
[email protected]
The Trout Group LLC
(646) 378-2933
